Search research articles
Contact Us
Filters
Showing results (441-450 of 562) with videos related to
Page
of 57
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 20, 2014
The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents
Veronika Dunkl, Corvin Cleff, Gabriele Stoffels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network
Michael Weller, Jörg Felsberg, Christian Hartmann, et al.
Neuro-Oncology
|
August 30, 2024
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas
Felix Sahm, Kenneth D Aldape, Priscilla K Brastianos, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 21, 2014
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET
Norbert Galldiks, Veronika Dunkl, Gabriele Stoffels, et al.
Neuro-Oncology Advances
|
December 11, 2020
Improved risk stratification in younger <i>IDH</i> wild-type glioblastoma patients by combining a 4-miRNA signature with <i>MGMT</i> promoter methylation status
Kristian Unger, Daniel F Fleischmann, Viktoria Ruf, et al.
Neuro-Oncology
|
July 8, 2022
Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions
Marcel Buehler, Xiao Yi, Weigang Ge, et al.
Archives of Pathology & Laboratory Medicine
|
June 21, 2019
Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting
David N Louis, Pieter Wesseling, Sebastian Brandner, et al.
Neuro-Oncology
|
July 17, 2014
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial
Benedikt Wiestler, David Capper, Volker Hovestadt, et al.
Neurology
|
September 27, 2013
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wolfgang Wick, Christoph Meisner, Bettina Hentschel, et al.
Brain Pathology (Zurich, Switzerland)
|
August 31, 2025
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors
Pieter Wesseling, David Capper, Guido Reifenberger, et al.
Page
of 57
Search research articles
Search
Showing results (441-450 of 562) with videos related to
Sort By:
Page
of 57
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 20, 2014
The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents
Veronika Dunkl, Corvin Cleff, Gabriele Stoffels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network
Michael Weller, Jörg Felsberg, Christian Hartmann, et al.
Neuro-Oncology
|
August 30, 2024
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas
Felix Sahm, Kenneth D Aldape, Priscilla K Brastianos, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 21, 2014
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET
Norbert Galldiks, Veronika Dunkl, Gabriele Stoffels, et al.
Neuro-Oncology Advances
|
December 11, 2020
Improved risk stratification in younger <i>IDH</i> wild-type glioblastoma patients by combining a 4-miRNA signature with <i>MGMT</i> promoter methylation status
Kristian Unger, Daniel F Fleischmann, Viktoria Ruf, et al.
Neuro-Oncology
|
July 8, 2022
Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions
Marcel Buehler, Xiao Yi, Weigang Ge, et al.
Archives of Pathology & Laboratory Medicine
|
June 21, 2019
Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting
David N Louis, Pieter Wesseling, Sebastian Brandner, et al.
Neuro-Oncology
|
July 17, 2014
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial
Benedikt Wiestler, David Capper, Volker Hovestadt, et al.
Neurology
|
September 27, 2013
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wolfgang Wick, Christoph Meisner, Bettina Hentschel, et al.
Brain Pathology (Zurich, Switzerland)
|
August 31, 2025
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors
Pieter Wesseling, David Capper, Guido Reifenberger, et al.
Page
of 57